Blog TrialX An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York AngIV Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP PS1 Mouse via the PI3K AKT Signaling Pathway Clinical Research in 2026:What's Changing and Why It Matters